WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014193881) CRYSTALLINE FORM OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1 H-PYRAZOL-3-YLAMINO)-6-ETHYL-1 -METHYL-1,6-DIHYRDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE-7-CARBOXAMIDE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/193881 International Application No.: PCT/US2014/039657
Publication Date: 04.12.2014 International Filing Date: 28.05.2014
IPC:
C07D 471/14 (2006.01) ,A61K 31/437 (2006.01) ,A61P 35/00 (2006.01) ,A61P 37/00 (2006.01)
Applicants: BRISTOL-MYERS SQUIBB COMPANY[US/US]; Route 206 and ProvinceLine Road Princeton, New Jersey 08543, US
Inventors: TAMEZE, Shella; US
Agent: KORSEN, Elliott; US
Priority Data:
61/828,76030.05.2013US
Title (EN) CRYSTALLINE FORM OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1 H-PYRAZOL-3-YLAMINO)-6-ETHYL-1 -METHYL-1,6-DIHYRDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE-7-CARBOXAMIDE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS
(FR) FORME CRISTALLINE DE N,N-DICYCLOPROPYL-4-(1,5-DIMÉTHYL-1H-PYRAZOL-3-YLAMINO)-6-ÉTHYL-1-MÉTHYL-1,6-DIHYDRO-IMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE-7-CARBOXAMIDE POUR LE TRAITEMENT DE TROUBLES MYÉLOPROLIFÉRATIFS
Abstract: front page image
(EN) Crystalline form, Form N-2, of N, Ndicyclopropyl-4-(l,5-dimethyl-1 Hpyrazol-3-ylamino)-6-ethyl-l-methyl-l,6-dihydroimidazo[4,5- d]pyrrolo[2,3-b]pyridine-7-carboxamide (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising Form N-2 of Compound I as well as a method of using the Form N-2 of Compound I in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.
(FR) L'invention concerne une forme cristalline, la forme N-2, de N,Ndicyclopropyl-4-(1,5-diméthyl-1Hpyrazol-3-ylamino)-6-éthyl-1-méthyl-1,6-dihydro-imidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (Composé I). L'invention concerne également une composition pharmaceutique et une forme posologique orale comprenant la forme N-2 du composé I, ainsi qu'une méthode d'utilisation de la forme N-2 du composé I dans le traitement de troubles myéloprolifératifs, qui comprennent la polyglobulie primitive, la thrombocytémie et la myélofibrose primaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)